Acorda Therapeutics, Inc. 3,750,000 Shares Common Stock UNDERWRITING AGREEMENT dated June 7, 2007 Banc of America Securities LLC Deutsche Bank Securities Inc.Underwriting Agreement • June 8th, 2007 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Introductory. Acorda Therapeutics, Inc., a Delaware corporation (the “Company), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 3,626,960 shares of its Common Stock, par value $0.001 per share (the “Common Stock”); and the stockholders of the Company named in Schedule B (collectively, the “Selling Stockholders”) severally propose to sell to the Underwriters an aggregate of 123,040 shares of Common Stock. The 3,626,960 shares of Common Stock to be sold by the Company and the 123,040 shares of Common Stock to be sold by the Selling Stockholders are collectively called the “Firm Common Shares”. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 562,500 shares (the “Optional Common Shares”) of Common Stock, as provided in Section 2. The Firm Common Shares and, if and to the extent such option is exercised, the Optional Common Shares are collectively called the “Common Shares”. Ba
